Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysisChristoph Stettler, Peter Jüni, Simon Wandel et al.|The Lancet|2007Cited by 1.4k
Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trialThomas Engstrøm, Lars Køber, Kari Saunamäki et al.|The Lancet|2015Cited by 966
Comparison of Zotarolimus- and Everolimus-Eluting Coronary StentsJavaid Iqbal, Stephan Windecker, Patrick W. Serruys et al.|Circulation Cardiovascular Interventions|2015Cited by 152
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trialAlexandra J. Lansky, Andreas Baumbach, William Wijns et al.|The Lancet|2018Cited by 61